跳至主要内容
临床试验/NCT05333055
NCT05333055终止不适用

Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema

Greater Houston Retina Research1 个研究点 分布在 1 个国家目标入组 107 人开始时间: 2022年2月10日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
107
试验地点
1
主要终点
Aqueous Humor Levels of Disease State Biomarkers

研究概览

简要总结

The DRAGONS study is a non-interventional, prospective study that will

  1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various stages of diabetic retinopathy (DR) and diabetic macular edema (DME) as well as other retinal pathologies, and
  2. correlate a broad array of aqueous humor disease state biomarkers with DR severity, DME anti-vascular endothelial growth factor (VEGF) responsiveness, and other retinal pathologies.

详细描述

The DRAGONS study is a non-interventional study investigating aqueous humor biomarker levels in patients with various stages of DR, DME and other retinal pathologies.

Subjects will be included in the study if at least one eye meets any of the following criteria:

Group 1 - eyes with treatment naive DR with or without DME Group 2 - eyes with DME that are incompletely responsive to anti-VEGF therapy Group 3 - eyes with various retinal conditions including eyes with DR and DME that are anti-VEGF responsive as well as non-exudative retinal pathologies such as epiretinal membrane and macular hole

The study will consist of a single visit and a retrospective chart review. The study visit will consist of:

  1. Screening for eligibility;
  2. Aqueous humor collection;
  3. Blood collection;
  4. Optical coherence tomography;
  5. Optical coherence tomography angiography;
  6. Fundus photography; and
  7. Fluorescein angiography.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects with at least one of the following retinal conditions in at least one eye:
  • Treatment naive diabetic retinopathy (group 1 only);
  • Diabetic retinopathy with DME that is incompletely responsive to anti-VEGF therapy at principal investigators discretion with retinal thickening documented on OCT (group 2 only);
  • Various retinal disease including but not limited to diabetic retinopathy without DME which has previously been treated, DME which has responded to anti-VEGF therapy, neovascular age-related macular degeneration, branch or central retinal vein occlusions, epiretinal membrane, or macular hole (group 3 only)

排除标准

  • Prior intraocular or subtenon steroid injection in the study eye within the prior 1 year of signing informed consent;
  • Prior focal or grid laser photocoagulation in the study eye if within 90 days of signing informed consent;
  • Prior panretinal photocoagulation in the study eye if within 90 days of signing informed consent;
  • Intraocular or refractive surgery in the study eye within 90 days of signing informed consent;
  • Systemic anti-VEGF treatment within 90 days of signing informed consent

结局指标

主要结局

Aqueous Humor Levels of Disease State Biomarkers

时间窗: Baseline

Aqueous humor levels of cytokines, KKS metabolites, and cell adhesion molecules of subjects with various stages of diabetic retinopathy and diabetic macular edema as well as other retinal pathologies.

次要结局

  • Correlation of Biomarker Levels(Baseline)

研究者

发起方
Greater Houston Retina Research
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验